The enhancement of contextual fear conditioning by ABT-418.
Activation of nicotinic acetylcholine receptors (nAChRs) is known to modulate various forms of learning and memory, including contextual fear conditioning. Although numerous studies have shown that high-affinity beta2-containing nAChRs are necessary for the nicotine-induced enhancement of contextual fear conditioning, it is unknown whether other high-affinity nAChR agonists are capable of enhancing this learning. To examine this issue, ABT-418, a high-affinity nAChR agonist with greater selectivity for high-affinity receptors than nicotine, was administered before acquisition and/or recall of contextual fear memories. ABT-418 enhanced acquisition of contextual fear memories in a dose-dependent manner.
Kenney
Justin W
JW
Department of Psychology, Temple University, Philadelphia, Pennsylvania 19122, USA.
Wilkinson
Derek S
DS
Gould
Thomas J
TJ
D000161:Acoustic Stimulation / Q000009:adverse effects; D000818:Animals; D014151:Anti-Anxiety Agents / Q000494:pharmacology*; D001703:Biophysics; D003214:Conditioning, Classical / Q000187:drug effects*; D004597:Electroshock / Q000009:adverse effects; D005239:Fear / Q000187:drug effects*; D007555:Isoxazoles / Q000494:pharmacology*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D009043:Motor Activity / Q000187:drug effects; D011759:Pyrrolidines / Q000494:pharmacology*; D018709:Statistics, Nonparametric; D014828:Vocalization, Animal / Q000187:drug effects
D014151:Anti-Anxiety Agents; D007555:Isoxazoles; D011759:Pyrrolidines; C088383:3-methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole
Am J Psychiatry. 1999 Dec;156(12):1931-7
10588407
J Pharmacol Exp Ther. 1997 Mar;280(3):1117-36
9067295
J Neurosci. 1991 Mar;11(3):837-45
1705971
Behav Neurosci. 2008 Oct;122(5):1158-65
18823171
J Med Chem. 1997 Dec 19;40(26):4169-94
9435889
Brain Res Mol Brain Res. 1992 Dec;16(3-4):339-44
1337943
Psychopharmacology (Berl). 1999 May;144(2):175-82
10394999
Neuropharmacology. 2003 Jun;44(8):1054-67
12763099
Acta Pharmacol Sin. 2009 Jun;30(6):752-60
19434057
Psychopharmacology (Berl). 1999 Mar;142(4):334-42
10229057
Br J Pharmacol. 1997 Feb;120(3):429-38
9031746
Neuropsychopharmacology. 2009 Aug;34(9):2167-79
19404242
Psychopharmacology (Berl). 2007 Feb;190(3):343-52
17136517
Rev Physiol Biochem Pharmacol. 2003;147:1-46
12783266
Psychopharmacology (Berl). 1997 Apr;130(3):276-84
9151363
Psychopharmacology (Berl). 1998 Mar;136(1):50-8
9537682
Annu Rev Physiol. 1995;57:521-46
7778876
Science. 1992 May 1;256(5057):675-7
1585183
J Comp Neurol. 1989 Jun 8;284(2):314-35
2754038
Mol Neurobiol. 2008 Aug;38(1):101-21
18690555
J Physiol. 1994 Nov 15;481 ( Pt 1):27-34
7853248
Neuroscience. 2004;129(1):11-24
15489024
Neurosci Biobehav Rev. 2004 Nov;28(7):675-85
15555677
J Pharmacol Exp Ther. 1994 Jul;270(1):319-28
7913497
Neuropharmacology. 2009 Jan;56(1):237-46
18723036
Behav Brain Res. 2004 Nov 5;155(1):167-73
15325790
J Pharmacol Exp Ther. 1994 Jul;270(1):310-8
7518514